Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis

Abstract The wider use of clozapine is limited by the risk of agranulocytosis and the associated requirement for monitoring of neutrophil counts. We searched local electronic patient records for cases of agranulocytosis occurring during clozapine treatment during the period 2007–2020. We found 23 ep...

Full description

Bibliographic Details
Main Authors: David Taylor, Kalliopi Vallianatou, Eromona Whiskey, Olubanke Dzahini, James MacCabe
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:npj Schizophrenia
Online Access:https://doi.org/10.1038/s41537-022-00232-0
_version_ 1797642827715313664
author David Taylor
Kalliopi Vallianatou
Eromona Whiskey
Olubanke Dzahini
James MacCabe
author_facet David Taylor
Kalliopi Vallianatou
Eromona Whiskey
Olubanke Dzahini
James MacCabe
author_sort David Taylor
collection DOAJ
description Abstract The wider use of clozapine is limited by the risk of agranulocytosis and the associated requirement for monitoring of neutrophil counts. We searched local electronic patient records for cases of agranulocytosis occurring during clozapine treatment during the period 2007–2020. We found 23 episodes recorded as agranulocytosis in clozapine patients. Of these, nine met pre-defined criteria and were considered episodes of life-threatening agranulocytosis (LTA). These episodes of clozapine-induced LTA exhibited a distinct pattern of continuous and rapid neutrophil count decline to zero or near zero. Mean time for neutrophils to fall from ANC > 2 to ANC <0.5 × 109/L was 8.4 days (range 2–15 days). Each event was also characterised by a prolonged nadir and delayed recovery (range 4–16 days). Non-LTA episodes were, in contrast, brief and benign. We conclude that an important proportion of cases of agranulocytosis identified in people prescribed clozapine are not life-threatening and may not even be clozapine-related. Monitoring schemes should aim to identify true clozapine-induced LTA as opposed to threshold-defined nominal agranulocytosis. Genetics studies might benefit from examining associations with clozapine-induced LTA rather than with recorded cases of agranulocytosis or neutropenia.
first_indexed 2024-03-11T14:05:55Z
format Article
id doaj.art-2010d91e70e34923aba72fc54f5700d0
institution Directory Open Access Journal
issn 2334-265X
language English
last_indexed 2024-03-11T14:05:55Z
publishDate 2022-03-01
publisher Nature Portfolio
record_format Article
series npj Schizophrenia
spelling doaj.art-2010d91e70e34923aba72fc54f5700d02023-11-02T02:01:02ZengNature Portfolionpj Schizophrenia2334-265X2022-03-01811910.1038/s41537-022-00232-0Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosisDavid Taylor0Kalliopi Vallianatou1Eromona Whiskey2Olubanke Dzahini3James MacCabe4Institute of Pharmaceutical Science, King’s College LondonPharmacy Department, Maudsley HospitalInstitute of Pharmaceutical Science, King’s College LondonInstitute of Pharmaceutical Science, King’s College LondonNational Psychosis Unit, Bethlem Royal HospitalAbstract The wider use of clozapine is limited by the risk of agranulocytosis and the associated requirement for monitoring of neutrophil counts. We searched local electronic patient records for cases of agranulocytosis occurring during clozapine treatment during the period 2007–2020. We found 23 episodes recorded as agranulocytosis in clozapine patients. Of these, nine met pre-defined criteria and were considered episodes of life-threatening agranulocytosis (LTA). These episodes of clozapine-induced LTA exhibited a distinct pattern of continuous and rapid neutrophil count decline to zero or near zero. Mean time for neutrophils to fall from ANC > 2 to ANC <0.5 × 109/L was 8.4 days (range 2–15 days). Each event was also characterised by a prolonged nadir and delayed recovery (range 4–16 days). Non-LTA episodes were, in contrast, brief and benign. We conclude that an important proportion of cases of agranulocytosis identified in people prescribed clozapine are not life-threatening and may not even be clozapine-related. Monitoring schemes should aim to identify true clozapine-induced LTA as opposed to threshold-defined nominal agranulocytosis. Genetics studies might benefit from examining associations with clozapine-induced LTA rather than with recorded cases of agranulocytosis or neutropenia.https://doi.org/10.1038/s41537-022-00232-0
spellingShingle David Taylor
Kalliopi Vallianatou
Eromona Whiskey
Olubanke Dzahini
James MacCabe
Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
npj Schizophrenia
title Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
title_full Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
title_fullStr Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
title_full_unstemmed Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
title_short Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
title_sort distinctive pattern of neutrophil count change in clozapine associated life threatening agranulocytosis
url https://doi.org/10.1038/s41537-022-00232-0
work_keys_str_mv AT davidtaylor distinctivepatternofneutrophilcountchangeinclozapineassociatedlifethreateningagranulocytosis
AT kalliopivallianatou distinctivepatternofneutrophilcountchangeinclozapineassociatedlifethreateningagranulocytosis
AT eromonawhiskey distinctivepatternofneutrophilcountchangeinclozapineassociatedlifethreateningagranulocytosis
AT olubankedzahini distinctivepatternofneutrophilcountchangeinclozapineassociatedlifethreateningagranulocytosis
AT jamesmaccabe distinctivepatternofneutrophilcountchangeinclozapineassociatedlifethreateningagranulocytosis